San Francisco, 8 April 2019: The Report Lung Cancer Diagnostics Market Analysis By Type (Small Cell Lung Cancer,
Non-small Cell Lung Cancer), By Test (Imaging Test, Biopsy, Sputum Cytology,
Molecular Testing), And Segment Forecasts To 2024
The global lung cancer diagnostics market is expected to reach USD 3,644.6 million by 2024,
according to a new report by Grand View Research Inc. The development of lung
cancer-specific biomarkers is one of the primary factors for the growth of the
lung cancer diagnostics market over the forecast period. These diagnostic tools
facilitate the personalized treatment approach of lung malignancies.
Various biomarkers are present in the
research pipeline. For instance, in November 2015, Epigenomics AG announced the
launch of a new blood-based test using DNA methylation biomarkers, the
development of which is underway. The initial results of this test revealed a
promising outcome in the early diagnosis of lung cancer.
Furthermore, various awareness programs
focusing on lung cancer and its associated symptoms are initiated in an attempt
to elevate the screening and diagnosis rates inindividuals at a high risk of
developing lung malignancies. For instance, November is considered as a lung
cancer awareness month across the UK, which is supported by the Roy Castle Lung
Cancer Foundation.
Access Research Report of Lung Cancer
Diagnostics Market @ http://www.grandviewresearch.com/industry-analysis/lung-cancer-diagnostics-market
Further key findings from the study suggest:
· The small cell lung cancer segment
accounted for around 15% market share in 2015. This is an aggressive subtype of
the lung malignancies, which has proven to be fatal within a short period of
time if left undiagnosed.
· Non-small cell lung cancer was identified
as the largest segment in 2015 with revenue of over USD 1,300.0 million. This
is majorly due to the availability of novel lung cancer diagnostics that
facilitate the detection of large tumor growths.
· The imaging tests segment was identified as
the largest revenue generating segment in 2015 with a market share of around
50%. Major factors responsible for the large market share include the frequent
use of various imaging techniques such as CT scan, X-ray, and MRI in the
detection of lung malignancies coupled with the increased availability of the
diagnostic tools.
· The molecular testing segment is expected
to grow at a profitable rate of around 10% over the forecast period. The
introduction of novel molecular testing techniques coupled with the increasing
number of investments to support the research and development efforts for the
development of biomarker-based molecular testing in lung cancer detection is
expected to foster the demand of this segment over the forecast period.
· In 2015, North America accounted for the
largest revenue share of over 30% majorly due to supportive government policies
in the region coupled with the availability of technology-enabled lung cancer
diagnostics
· Asia Pacific region is expected to reach a
revenue share of over 28% by 2024. Major factors responsible for the growth
include the constantly improving healthcare infrastructure, the growing
awareness of the disease symptoms, and a wide base of unmet clinical needs in
the developing countries in the region.
· Major players of this market include
bioMérieux, Roche Diagnostics, Qiagen N.V., Illumina Inc., Thermo Fisher
Scientific, Agilent Technologies, Janssen, AstraZeneca plc, and Sanofi S.A.
· Novel product launches in the lung cancer
diagnostics product portfolio is one of the major strategic initiatives adopted
by the market players. For instance, Orion genomics is involved in the
development of novel biomarkers for lung cancer diagnosis. Allegro Diagnostics
is involved in the development and commercialization of pulmonary
genomics-based lung cancer diagnostics.
Browse more reports of this category by Grand View
Research at: https://www.grandviewresearch.com/industry/clinical-diagnostics
Grand View
Research has segmented the global lung cancer diagnostics market on the basis
of type, test, and region:
Global Lung Cancer Diagnostics Type Outlook
(Revenue, USD Million, 2016 - 2024)
·
Small Cell Lung Cancer
·
Non-small Cell Lung Cancer
Global Lung Cancer Diagnostics Test Outlook
(Revenue, USD Million, 2016 - 2024)
·
Imaging Test
·
Biopsy
·
Sputum Cytology
·
Molecular Test
·
Others
Lung Cancer Diagnostics Regional Outlook (Revenue,
USD Million, 2016 - 2022)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
MEA
Access Press Release of
Lung Cancer Diagnostics Market@ https://www.grandviewresearch.com/press-release/global-lung-cancer-diagnostics-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment